tradmap

CADL Earnings Candel Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$2 -$1 $0 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $62500 $125000 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$55M -$28M $0 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$1 -$1 $0 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$39M -$16M $7M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-137% 43% 223% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–21 of 21
Q2 20262026-06-30-0.702026-08-1310-Q
Q1 20262026-03-31-0.142026-05-1410-Q
FY 20252025-12-31-0.722026-03-1210-K
Q3 20252025-09-30-0.172025-11-1310-Q
Q2 20262025-06-300.052026-08-1310-Q
Q1 20262025-03-310.132026-05-1410-Q
FY 20252024-12-31-1.742026-03-1210-K
Q3 20252024-09-30-1.352025-11-1310-Q
Q2 20252024-06-30-1.032025-08-1410-Q
Q1 20252024-03-31-0.282025-05-1310-Q
FY 20242023-12-31-1.312025-03-1310-K
Q3 20242023-09-30-0.932024-11-1410-Q
Q2 20242023-06-30-0.642024-08-1310-Q
Q1 20242023-03-31-0.302024-05-1410-Q
FY 20232022-12-31-0.652024-03-2810-K
Q3 20232022-09-30-0.482023-11-0910-Q
Q2 20232022-06-30-0.172023-08-1010-Q
Q1 20232022-03-31-0.032023-05-1110-Q
FY 20222021-12-31-1.912023-03-3010-K
Q3 20222021-09-30-2.422022-11-1010-Q
Q2 20222021-06-30-1.852022-08-0510-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.